PD-L2 is predominantly expressed by Th2 cells - PubMed (original) (raw)
Comment
PD-L2 is predominantly expressed by Th2 cells
W Joost Lesterhuis et al. Mol Immunol. 2011 Oct.
Abstract
In response to a recently published article by Messal et al. (2011) in which the authors show that PD-L2 is expressed by activated T cells and ligation results in suppression of T cell proliferation and cytokine secretion, we here report that PD-L2 is differentially expressed by the diverse Th subsets, with predominant expression by Th2 cells.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Comment on
- PD-L2 is expressed on activated human T cells and regulates their function.
Messal N, Serriari NE, Pastor S, Nunès JA, Olive D. Messal N, et al. Mol Immunol. 2011 Sep;48(15-16):2214-9. doi: 10.1016/j.molimm.2011.06.436. Epub 2011 Jul 12. Mol Immunol. 2011. PMID: 21752471
Similar articles
- PD-L2 is expressed on activated human T cells and regulates their function.
Messal N, Serriari NE, Pastor S, Nunès JA, Olive D. Messal N, et al. Mol Immunol. 2011 Sep;48(15-16):2214-9. doi: 10.1016/j.molimm.2011.06.436. Epub 2011 Jul 12. Mol Immunol. 2011. PMID: 21752471 - The roles of the new negative T cell costimulatory pathways in regulating autoimmunity.
Khoury SJ, Sayegh MH. Khoury SJ, et al. Immunity. 2004 May;20(5):529-38. doi: 10.1016/s1074-7613(04)00116-5. Immunity. 2004. PMID: 15142522 Review. - L2pB1: a new player in autoimmunity.
Zhong X, Rothstein TL. Zhong X, et al. Mol Immunol. 2011 Jun;48(11):1292-300. doi: 10.1016/j.molimm.2010.12.006. Epub 2010 Dec 31. Mol Immunol. 2011. PMID: 21195478 Free PMC article. Review. - PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. Latchman Y, et al. Nat Immunol. 2001 Mar;2(3):261-8. doi: 10.1038/85330. Nat Immunol. 2001. PMID: 11224527 - Time courses of B7 family molecules expressed on activated T-cells and their biological significance.
Sun ZW, Qiu YH, Shi YJ, Tao R, Chen J, Ge Y, Hu YM, Ma HB, Shi Q, Zhang XG. Sun ZW, et al. Cell Immunol. 2005 Jul-Aug;236(1-2):146-53. doi: 10.1016/j.cellimm.2005.08.021. Epub 2005 Sep 12. Cell Immunol. 2005. PMID: 16165113
Cited by
- Comparison of Clinical Trial Results of the Recently Approved Immunotherapeutic Drugs for Advanced Biliary Tract Cancers.
Das S. Das S. Rev Recent Clin Trials. 2024;19(2):81-90. doi: 10.2174/0115748871276666240123043710. Rev Recent Clin Trials. 2024. PMID: 38288802 Review. - KYNU-related transcriptome profile and clinical outcome from 2994 breast tumors.
Li Y, Wang M, Zhao L, Liang C, Li W. Li Y, et al. Heliyon. 2023 Jun 13;9(6):e17216. doi: 10.1016/j.heliyon.2023.e17216. eCollection 2023 Jun. Heliyon. 2023. PMID: 37383199 Free PMC article. - PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?
Ullah A, Pulliam S, Karki NR, Khan J, Jogezai S, Sultan S, Muhammad L, Khan M, Jamil N, Waheed A, Belakhlef S, Ghleilib I, Vail E, Heneidi S, Karim NA. Ullah A, et al. Clin Pract. 2022 Aug 24;12(5):653-671. doi: 10.3390/clinpract12050068. Clin Pract. 2022. PMID: 36136862 Free PMC article. Review. - The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment.
Guo Y, Xie Y, Luo Y. Guo Y, et al. Front Immunol. 2022 Feb 9;13:851004. doi: 10.3389/fimmu.2022.851004. eCollection 2022. Front Immunol. 2022. PMID: 35222443 Free PMC article. Review. - PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
Zhang Y, Chen X, Mo S, Ma H, Lu Z, Yu S, Chen J. Zhang Y, et al. J Pathol Clin Res. 2022 May;8(3):257-267. doi: 10.1002/cjp2.259. Epub 2022 Jan 17. J Pathol Clin Res. 2022. PMID: 35037417 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials